Remove Ethics Remove Patients Remove Prescription Remove Safety
article thumbnail

The Dark Side of KOL Relationship

Contrarian Sales Techniques

While building and maintaining relationships with key opinion leaders (KOLs) and thought leaders is an essential part of a pharmaceutical sales representative's job, there have been cases where reps have misused their relationship with KOLs to influence prescriptions. One of the most notable cases was the Vioxx scandal in the early 2000s.

Ethics 52
article thumbnail

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical trials and pregnancy: regulators weigh in

Clarivate

How feasible is it to establish a drug’s safety for use in a population that may be unwilling or unable to participate in clinical trials? Margolis Center for Health Policy to convene a February 2021 public meeting about scientific and ethical issues associated with enrolling pregnant individuals in clinical trials for drug development.

article thumbnail

The Mom, The Myth, The Med Rep In Trauma Sales With Julia Greenspan

Evolve Your Success

For patients who are chronically ill or if you’ve ever been in a trauma situation, you have someone with a large open wound and things that can’t be closed right away, there are a lot of things that they can do to speed along the recovery process for that soft tissue damage. You’re getting direct patient contact.

Sales 52
article thumbnail

The Future of RWE in Clinical Trial Design and Recruitment

Clarify Health

Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; and 80 percent of studies do not meet enrollment deadlines. Dr. Rizk provided an example of how we’re getting better at meeting patients where they are. Below are highlights and key takeaways from the panel.

article thumbnail

The Future of RWE in Clinical Trial Design and Recruitment

Clarify Health

Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; and 80 percent of studies do not meet enrollment deadlines. Dr. Rizk provided an example of how we’re getting better at meeting patients where they are. Below are highlights and key takeaways from the panel.

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. Dr. Barry DeCoster, PhD, an associate professor of bioethics at the University of Michigan, describes gender affirming care as “safe and effective” for most patients.

Ethics 144